Article

Bausch + Lomb enrolls first patient in LASIK clinical trial

Trial is evaluating the use of the Technolas TENEO excimer laser for vision correction surgery for hyperopia with astigmatism.

Bausch + Lomb Corp. today announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas TENEO excimer laser for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism.

“The initiation of this study is an important step toward our goal of bringing the Technolas TENEO excimer laser to the United States, where, if approved, it could become the first significant LASIK innovation in more than a decade," Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb, said in a statement. "The TENEO laser has been well received and is widely adopted in more than 50 markets around the world as one of the most versatile lasers available with a compact footprint."

According to the company, the multicenter, prospective, single arm, open-label, non-randomized clinical study will include up to 334 operative (study) eyes undergoing LASIK surgery for correction of hyperopia and hyperopic astigmatism. Investigators will determine safety and efficacy endpoints through a series of post-operative visits up to 24 months based on post-surgical observation.

“The demand for LASIK vision correction has risen significantly among our patients over the past few years, and refractive surgeons want options that meet the needs of their patients,” Ralph Chu, MD, study investigator, and founder and medical director of Chu Vision Institute and Chu Surgery Center, Bloomington, Minn., said in a news release. “This study represents an exciting opportunity to evaluate new technology that has the potential to help more hyperopic patients.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
© 2025 MJH Life Sciences

All rights reserved.